UBS Group’s Catalyst Pharmaceutical CPRX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $24.4M | Buy |
986,090
+337,103
| +52% | +$8.03M | ﹤0.01% | 2375 |
|
|
2025
Q4 | $15.1M | Buy |
648,987
+55,378
| +9% | +$1.23M | ﹤0.01% | 2865 |
|
|
2025
Q3 | $11.7M | Sell |
593,609
-251,168
| -30% | -$5.17M | ﹤0.01% | 3120 |
|
|
2025
Q2 | $18.3M | Buy |
844,777
+85,373
| +11% | +$2.02M | ﹤0.01% | 2454 |
|
|
2025
Q1 | $18.4M | Buy |
759,404
+36,546
| +5% | +$823K | ﹤0.01% | 2413 |
|
|
2024
Q4 | $15.1M | Buy |
722,858
+510,013
| +240% | +$11M | ﹤0.01% | 2640 |
|
|
2024
Q3 | $4.23M | Buy |
212,845
+43,454
| +26% | +$806K | ﹤0.01% | 3245 |
|
|
2024
Q2 | $2.62M | Sell |
169,391
-219,708
| -56% | -$3.42M | ﹤0.01% | 3481 |
|
|
2024
Q1 | $6.2M | Sell |
389,099
-80,217
| -17% | -$1.21M | ﹤0.01% | 2741 |
|
|
2023
Q4 | $7.89M | Buy |
469,316
+128,595
| +38% | +$1.76M | ﹤0.01% | 2306 |
|
|
2023
Q3 | $3.98M | Sell |
340,721
-16,804
| -5% | -$225K | ﹤0.01% | 2796 |
|
|
2023
Q2 | $4.81M | Sell |
357,525
-30,145
| -8% | -$434K | ﹤0.01% | 2632 |
|
|
2023
Q1 | $6.43M | Sell |
387,670
-202,612
| -34% | -$3.34M | ﹤0.01% | 2281 |
|
|
2022
Q4 | $11M | Buy |
590,282
+261,239
| +79% | +$4.02M | ﹤0.01% | 1853 |
|
|
2022
Q3 | $4.22M | Buy |
329,043
+4,031
| +1% | +$47.8K | ﹤0.01% | 2509 |
|
|
2022
Q2 | $2.28M | Buy |
325,012
+10,497
| +3% | +$77K | ﹤0.01% | 3049 |
|
|
2022
Q1 | $2.61M | Buy |
314,515
+24,848
| +9% | +$176K | ﹤0.01% | 3177 |
|
|
2021
Q4 | $1.96M | Sell |
289,667
-153,247
| -35% | -$1.01M | ﹤0.01% | 3754 |
|
|
2021
Q3 | $2.35M | Buy |
442,914
+46,253
| +12% | +$253K | ﹤0.01% | 3445 |
|
|
2021
Q2 | $2.28M | Sell |
396,661
-162,331
| -29% | -$838K | ﹤0.01% | 3464 |
|
|
2021
Q1 | $2.58M | Buy |
558,992
+229,401
| +70% | +$911K | ﹤0.01% | 3305 |
|
|
2020
Q4 | $1.1M | Buy |
329,591
+53,741
| +19% | +$181K | ﹤0.01% | 3939 |
|
|
2020
Q3 | $819K | Buy |
+275,850
| New | +$1.08M | ﹤0.01% | 3783 |
|
|
2020
Q2 | – | Sell |
-2,275
| Closed | -$9K | – | 7983 |
|
|
2020
Q1 | $9K | Sell |
2,275
-15,900
| -87% | -$65.3K | ﹤0.01% | 6980 |
|
|
2019
Q4 | $68K | Sell |
18,175
-208,305
| -92% | -$974K | ﹤0.01% | 6192 |
|
|
2019
Q3 | $1.2M | Buy |
226,480
+204,220
| +917% | +$1.09M | ﹤0.01% | 3805 |
|
|
2019
Q2 | $85K | Buy |
+22,260
| New | +$96.2K | ﹤0.01% | 5487 |
|
|
2019
Q1 | – | Sell |
-35,811
| Closed | -$69K | – | 7773 |
|
|
2018
Q4 | $69K | Buy |
35,811
+12,540
| +54% | +$35.9K | ﹤0.01% | 5841 |
|
|
2018
Q3 | $88K | Buy |
23,271
+11,073
| +91% | +$34.7K | ﹤0.01% | 5696 |
|
|
2018
Q2 | $38K | Buy |
+12,198
| New | +$37K | ﹤0.01% | 6208 |
|
|
2018
Q1 | – | Sell |
-10,703
| Closed | -$42K | – | 7854 |
|
|
2017
Q4 | $42K | Buy |
10,703
+8,299
| +345% | +$27.4K | ﹤0.01% | 5973 |
|
|
2017
Q3 | $6K | Sell |
2,404
-3,641
| -60% | -$9.99K | ﹤0.01% | 7136 |
|
|
2017
Q2 | $17K | Buy |
+6,045
| New | +$12.6K | ﹤0.01% | 6403 |
|
|
2016
Q3 | – | Sell |
-53,536
| Closed | -$38K | – | 7700 |
|
|
2016
Q2 | $38K | Buy |
+53,536
| New | +$43.1K | ﹤0.01% | 5734 |
|
|
2015
Q3 | – | Sell |
-3,183
| Closed | -$13K | – | 8436 |
|
|
2015
Q2 | $13K | Buy |
+3,183
| New | +$12.7K | ﹤0.01% | 7253 |
|
Other funds holding CPRX
VCM
DM
VPM
UBS Group's CPRX Position: Q1 2026 in Review
UBS Group increased its Catalyst Pharmaceutical (CPRX) stake by 52% in Q1 2026, buying an estimated $8.03M and bringing the position to 986,090 shares worth $24.4M. The position accounts for ﹤0.01% of the portfolio, ranked #2375.
UBS Group first reported a position in CPRX in Q2 2015 and has held it in 35 quarters since. 380 funds tracked by Wall St. Rank hold CPRX as of Q1 2026.
- UBS Group held 986,090 shares of Catalyst Pharmaceutical worth $24.4M as of Q1 2026.
- UBS Group bought 337,103 Catalyst Pharmaceutical shares in Q1 2026, an estimated $8.03M.
- Catalyst Pharmaceutical made up ﹤0.01% of UBS Group's portfolio in Q1 2026, its #2375 holding.
- UBS Group first reported a position in Catalyst Pharmaceutical in Q2 2015 and has held it in 35 quarters since.
- 380 funds tracked by Wall St. Rank held Catalyst Pharmaceutical as of Q1 2026.
Based on UBS Group's 13F filing for Q1 2026, filed 5 May 2026.